Editing Pregabalin

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.

The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.

Latest revision Your text
Line 116: Line 116:
*July 2012, the U.S. [[Food and Drug Administration]] (FDA) approved a generic version of Lyrica. Pregabalin, the active ingredient, is the generic name.<ref>{{Cite news | url=https://www.reuters.com/article/us-lupin-lyrica-idUSBRE8640Y220120705| title = U.S. OKs Lupin generic of Pfizer nerve pain drug | last = | first = | date = 2012-07-05|work=Reuters|access-date=2021-03-09|archive-url=|archive-date=|url-status=|language=en|quote=}}</ref>  Two weeks after being approved by the FDA, marketing was blocked by  Pfizer.<ref name=":2" />
*July 2012, the U.S. [[Food and Drug Administration]] (FDA) approved a generic version of Lyrica. Pregabalin, the active ingredient, is the generic name.<ref>{{Cite news | url=https://www.reuters.com/article/us-lupin-lyrica-idUSBRE8640Y220120705| title = U.S. OKs Lupin generic of Pfizer nerve pain drug | last = | first = | date = 2012-07-05|work=Reuters|access-date=2021-03-09|archive-url=|archive-date=|url-status=|language=en|quote=}}</ref>  Two weeks after being approved by the FDA, marketing was blocked by  Pfizer.<ref name=":2" />


*2014, Pfizer Inc., the maker of Lyrica, successfully blocked the marketing of Pregabalin generics until December of 2018 arguing that the generics should not be marketed and made available until their patent ran out.<ref>{{Cite news | url=https://www.bloomberg.com/news/articles/2014-02-06/pfizer-wins-ruling-to-block-generic-lyrica-until-2018| title = Pfizer Wins Ruling to Block Generic Lyrica Until 2018 | last = Decker | first = Susan | date = Feb 6, 2014|work=Bloomberg Business|access-date=|archive-url=|archive-date=|url-status=}}</ref> Warner-Lamber, (a subsidiary of Pfizer), "still holds a “second medical use” patent for the use of pregabalin in the treatment of peripheral and central neuropathic pain, which expires in July 2017. A second medical use patent is one that relates to a new medical use for a known compound."<ref>{{Cite journal | last = Wise | first = Jacqui | date = 2015-03-30| title = Doctors are warned not to prescribe generic pregabalin for pain control|url=https://www.bmj.com/content/350/bmj.h1724|journal=BMJ|language=en|volume=350|pages=h1724|doi=10.1136/bmj.h1724|issn=1756-1833|pmid=25825288}}</ref>
*2014, Pfizer Inc., the maker of Lyrica, successfully blocked the marketing of Pregabalin generics until December of 2018 arguing that the generics should not be marketed and made available until their patent ran out.<ref>{{Cite news | url=https://www.bloomberg.com/news/articles/2014-02-06/pfizer-wins-ruling-to-block-generic-lyrica-until-2018| title = Pfizer Wins Ruling to Block Generic Lyrica Until 2018 | last = Decker | first = Susan | date = Feb 6, 2014|work=Bloomberg Business|access-date=|archive-url=|archive-date=|url-status=}}</ref> Warner-Lamber, (a subsidiary of Pfizer), "still holds a “second medical use” patent for the use of pregabalin in the treatment of peripheral and central neuropathic pain, which expires in July 2017. A second medical use patent is one that relates to a new medical use for a known compound."<ref>{{Cite journal | last = Wise | first = Jacqui | date = 2015-03-30| title = Doctors are warned not to prescribe generic pregabalin for pain control|url=https://www.bmj.com/content/350/bmj.h1724|journal=BMJ|language=en|volume=350|pages=h1724|doi=10.1136/bmj.h1724|issn=1756-1833|pmid=25825288}}</ref>
* Nov 2018, [https://investors.pfizer.com/investor-news/press-release-details/2018/Pfizer-Receives-Six-Months-Pediatric-Exclusivity-for-LYRICA-pregabalin/default.aspx Pfizer Receives Six Months Pediatric Exclusivity For Lyrica® (Pregabalin)]<ref name=":02">{{Cite web|url=https://investors.pfizer.com/investor-news/press-release-details/2018/Pfizer-Receives-Six-Months-Pediatric-Exclusivity-for-LYRICA-pregabalin/default.aspx| title = Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin) | last = | first = | authorlink =  | date = Nov 27, 2018 | website = investors.pfizer.com|language=en-US|archive-url=|archive-date=|url-status=|access-date=2018-12-27}}</ref>
* Nov 2018, [https://investors.pfizer.com/investor-news/press-release-details/2018/Pfizer-Receives-Six-Months-Pediatric-Exclusivity-for-LYRICA-pregabalin/default.aspx Pfizer Receives Six Months Pediatric Exclusivity For Lyrica® (Pregabalin)]<ref name=":02">{{Cite web|url=https://investors.pfizer.com/investor-news/press-release-details/2018/Pfizer-Receives-Six-Months-Pediatric-Exclusivity-for-LYRICA-pregabalin/default.aspx| title = Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin) | last = | first = | authorlink =  | date = Nov 27, 2018 | website = investors.pfizer.com|language=en-US|archive-url=|archive-date=|url-status=|access-date=2018-12-27}}</ref>
<blockquote>Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for LYRICA<sup>®</sup>. This grant extends the period of U.S. market exclusivity for LYRICA by an additional six months, to June 30, 2019.<ref name=":02" /></blockquote>
<blockquote>Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for LYRICA<sup>®</sup>. This grant extends the period of U.S. market exclusivity for LYRICA by an additional six months, to June 30, 2019.<ref name=":02" /></blockquote>
Please make sure your edits are consistent with MEpedia's guidelines. By saving changes, you agree to the Terms of use, and you irrevocably agree to release your contribution under the CC BY-SA 3.0 License and the GFDL. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel Editing help (opens in new window)